Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chengcheng Gong

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Frontiers in Endocrinology|December 6, 2024
Clinicopathological characteristics, evolution, and treatment outcomes of hormone receptor-negative/HER2-low metastatic breast cancer: a pooled analysis of individual patient data from three prospective clinical trialsShihui Hu, Yannan Zhao, Yizhao Xie, et al.
Therapeutics and Clinical Risk Management|July 9, 2020
Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World ExperienceYi Li, Yizhao Xie, Chengcheng Gong, et al.
Therapeutic Advances in Medical Oncology|December 18, 2023
ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumorsShuhui You, Yizhao Xie, Mengjing Ji, et al.
Frontiers in Oncology|March 21, 2020
Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective StudyYi Li, Chengcheng Gong, Qianyi Lu, et al.
Cancers|July 27, 2022
Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by <sup>18</sup>F-FES PETYizhao Xie, Xinyue Du, Yannan Zhao, et al.
American Journal of Cancer Research|November 27, 2015
MicroRNA-320a inhibits proliferation and invasion of breast cancer cells by targeting RAB11ABiyun Wang, Ziang Yang, Hong Wang, et al.
Iscience|February 1, 2021
Intragenic DNA methylation regulates insect gene expression and reproduction through the MBD/Tip60 complexGuanfeng Xu, Hao Lyu, Yangqin Yi, et al.
Cancer Management and Research|July 17, 2019
Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a "PET biopsy" methodYizhao Xie, Bingxin Gu, Xichun Hu, et al.
Oncotarget|November 16, 2017
A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancerYannan Zhao, Chengcheng Gong, Zhonghua Wang, et al.
The Oncologist|August 8, 2018
Pretreatment <sup>18</sup>F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast CancerChengcheng Gong, Guang Ma, Xichun Hu, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Frontiers in Endocrinology|December 6, 2024
Clinicopathological characteristics, evolution, and treatment outcomes of hormone receptor-negative/HER2-low metastatic breast cancer: a pooled analysis of individual patient data from three prospective clinical trialsShihui Hu, Yannan Zhao, Yizhao Xie, et al.
Therapeutics and Clinical Risk Management|July 9, 2020
Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World ExperienceYi Li, Yizhao Xie, Chengcheng Gong, et al.
Therapeutic Advances in Medical Oncology|December 18, 2023
ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumorsShuhui You, Yizhao Xie, Mengjing Ji, et al.
Frontiers in Oncology|March 21, 2020
Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective StudyYi Li, Chengcheng Gong, Qianyi Lu, et al.
Cancers|July 27, 2022
Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by <sup>18</sup>F-FES PETYizhao Xie, Xinyue Du, Yannan Zhao, et al.
American Journal of Cancer Research|November 27, 2015
MicroRNA-320a inhibits proliferation and invasion of breast cancer cells by targeting RAB11ABiyun Wang, Ziang Yang, Hong Wang, et al.
Iscience|February 1, 2021
Intragenic DNA methylation regulates insect gene expression and reproduction through the MBD/Tip60 complexGuanfeng Xu, Hao Lyu, Yangqin Yi, et al.
Cancer Management and Research|July 17, 2019
Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a "PET biopsy" methodYizhao Xie, Bingxin Gu, Xichun Hu, et al.
Oncotarget|November 16, 2017
A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancerYannan Zhao, Chengcheng Gong, Zhonghua Wang, et al.
The Oncologist|August 8, 2018
Pretreatment <sup>18</sup>F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast CancerChengcheng Gong, Guang Ma, Xichun Hu, et al.
Pageof 5